ReviewThe Journal of clinical investigation2013
Isocitrate dehydrogenase mutations in leukemia.
Review in The Journal of clinical investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 75 citations in OpenAlex.
- Enabling Variant Proteogenomic Assay Development Through a Peptide Target Selection Pipeline and Web Application.Proteomics · 2026Article
- Review
- Scutellarin activates IDH1 to exert antitumor effects in hepatocellular carcinoma progression.Cell death & disease · 2024Article
- Isocitrate Dehydrogenase 1 and 2 Mutations in Pediatric Neuroblastoma Patients.Medeniyet medical journal · 2023Article
- D-2-Hydroxyglutarate Inhibits Calcineurin Phosphatase Activity to Abolish NF-AT Activation and IL-2 Induction in Stimulated Lymphocytes.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Context-Dependent Functions of KDM6 Lysine Demethylases in Physiology and Disease.Advances in experimental medicine and biology · 2023Article
- Role of cytokine in malignant T-cell metabolism and subsequent alternation in T-cell tumor microenvironment.Frontiers in oncology · 2023Review
- Transplantation in CML in the TKI era: who, when, and how?Hematology. American Society of Hematology. Education Program · 2022Article
- Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells.Neoplasia (New York, N.Y.) · 2022Article
- Redox Control of Integrin-Mediated Hepatic Inflammation in Systemic Autoimmunity.Antioxidants & redox signaling · 2022Review
- Put in a "CaCells · 2022Review
- Mechanism and prevention strategy of a bidirectional relationship between heart failure and cancer (Review).Experimental and therapeutic medicine · 2021Review
- Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.Molecular cell · 2021Article
- Narrative review of targetable features of pediatric acute myeloid leukemia from molecular and metabolic perspectives.Pediatric medicine (Hong Kong, China) · 2021Article
- (2Cancers · 2020Article
- Article
- Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.Cancer discovery · 2019Article
- It's complicated… mBiochimica et biophysica acta. Gene regulatory mechanisms · 2019Review
- Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice.Therapeutic advances in hematology · 2018Review
- Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates.Trends in cancer · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Recent genome-wide discovery studies have identified a spectrum of mutations in different malignancies and have led to the elucidation of novel pathways that contribute to oncogenic transformation. The discovery of mutations in the genes encoding isocitrate dehydrogenase (IDH) has uncovered a critical role for altered metabolism in oncogenesis, and the neomorphic, oncogenic function of IDH mutations affects several epigenetic and gene regulatory pathways. Here we discuss the relevance of IDH mutations to leukemia pathogenesis, therapy, and outcome and how mutations in IDH1 and IDH2 affect the leukemia epigenome, hematopoietic differentiation, and clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.